News

Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023

Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce its intention to commercialize TASCENSO ODT® (fingolimod) in the US multiple sclerosis (MS) market in Q1 2023. Eligible patients will receive full MS patient support program through Cycle Vita™

New US product, JAVYGTOR™ (sapropterin dihydrochloride) Tablets and Powder, launches for Phenylketonuria (PKU) treatment

Cycle Pharmaceuticals Limited (Cycle) is pleased to announce the launch of JAVYGTOR™ (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution, as a treatment option for patients with Phenylketonuria (PKU), approved by the US Food and Drug Administration (FDA).